Vektor Medical has secured a CE Mark for vMap, a non-invasive arrhythmia mapping solution. This development paves the way for European healthcare providers to utilize vMap’s capabilities in identifying and managing heart rhythm disorders.

A new investigation by The Schall Law Firm examines possible securities law violations by MoonLake Immunotherapeutics. Investors in the NASDAQ-listed company may have an opportunity to participate in a fraud claim if they believe they have been impacted by these allegations.

Mammotion’s robot lawn mowers let you maintain a pristine yard without manual effort. According to a recent Cnet report, you can take advantage of generous discounts—up to $1,100 off—to streamline your yard care routine.

Viridian Therapeutics has announced new inducement grants approved under Nasdaq Listing Rule 5635(c)(4). Released from Waltham, Mass. on October 2, 2025, this update highlights the company’s adherence to key regulatory requirements.

Deltec Asset Management LLC has expanded its stake in Ocular Therapeutix by 2.9% during the second quarter. In total, the firm owns 2,794,892 shares after purchasing an additional 78,519 shares, reflecting the importance of the biopharmaceutical company in Deltec’s overall portfolio.

DoorDash, based in San Francisco, is extending its services by offering two major new features: restaurant reservations and robot deliveries. Announced for some U.S. markets, these initiatives hint at the company’s ever-evolving approach to food service and technology.

Police in Northern California found themselves in an unusual predicament when they pulled over a driverless Waymo taxi after it executed an illegal U-turn. Despite the violation, no citation could be issued, highlighting new challenges in regulating autonomous vehicles.

In the past week, two newly listed companies—one in biotech and another in cybersecurity—saw insiders pour over $98 million into their shares, signaling strong confidence in their markets. A coal miner also attracted attention as a director increased their stake, joining several chief executives who have made similar moves.

Patton Fund Management Inc. has made a notable move by purchasing 10,132 shares of Moderna, Inc., valued at about $280,000. According to a recent SEC filing, this acquisition took place in the second quarter and aligns with similar investments by other hedge funds.

Wedbush analysts have lowered their 2029 earnings projection for Revolution Medicines, Inc. (NASDAQ: RVMD) from $1.47 to $1.23 per share. The updated report signals a more reserved stance on the biotech firm’s long-term performance outlook.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) has seen its projected earnings for 2026 revised downward. According to Leerink Partnrs’ recent report, the biotech company’s EPS forecast now stands at ($4.05) for fiscal year 2026.

Cantor Fitzgerald has revised its earnings projection for United Therapeutics, raising the biotechnology firm’s estimated 2025 earnings to $28.70 per share. The announcement points to growing confidence in the company’s potential for continued expansion.

Researchers at UC Berkeley recently unveiled HITTER, a new system that allows the Unitree G1 humanoid robot to play table tennis with impressive skill. The demonstration, published on August 28, 2025, quickly gained traction on X, sparking excitement about the future of robotics.

Woodline Partners LP has boosted its investment in CG Oncology (NASDAQ:CGON) by 21.5% during the first quarter. After purchasing an additional 135,472 shares, the firm now holds 764,357 shares worth $18,719,000, signaling a notable show of confidence in the biotech company’s future.

Castle Biosciences (NASDAQ: CSTL) received a resounding vote of confidence this week when Canaccord Genuity Group reaffirmed its “buy” rating. The firm’s price objective of $37.00 points to a potential 61.29% upside for the company’s shares.

Amazon’s Zoox is debuting its driverless taxi service in Las Vegas, offering free rides to curious passengers. This high-tech gamble highlights both safety concerns and the promise of next-level urban transport in the city where everything is a wager.

Tevogen Bio Holdings Inc. has announced that its Chief Information Officer and Head of Tevogen.AI, Mittul Mehta, will join a Startup Forum panel at the Databricks DATA + AI World Tour. Slated for October 8, 2025, in Boston, this appearance reflects Tevogen’s ongoing commitment to innovation in the field of artificial intelligence.

LiveBytes, a fast-moving feed from investingLive.com, offers traders and investors curated headlines and market insights as they happen. From gold’s record high to shifting monetary policy and AI-driven opportunities, it’s a one-stop resource for timely data and commentary.

LB Pharmaceuticals is seeking $228 million through an IPO on the Nasdaq, hoping to become the first biotech to go public since February. The New York-based firm plans to build on medicines that have long been used to treat schizophrenia, aiming to put a modern spin on an established therapy.

Scientists have identified a protein that, when switched off, appears to reverse age-related cognitive decline in mice. This breakthrough could offer promising new avenues for addressing conditions such as Alzheimer’s disease and age-related memory loss.

Eric Olson, Ph.D., of UT Southwestern Medical Center, has been awarded the 2025 Louisa Gross Horwitz Prize for his pioneering research on the genetic control of muscle development and emerging treatments for Duchenne muscular dystrophy. His work paves the way for critical breakthroughs in combating a life-threatening condition affecting both skeletal and cardiac muscle.